Tuesday, September 19, 2017

Only One-Quarter of Hepatitis C Patients Got Treatment Before Widespread DAA Use

Only One-Quarter of Hepatitis C Patients Got Treatment Before Widespread DAA Use
SEPTEMBER 19, 2017
Gail Connor Roche

Only one-quarter of patients worldwide with the chronic hepatitis C virus (HCV) received antiviral treatment before the widespread use of direct-acting antiviral (DAA) drugs, a review that considered almost 500,000 people has found.
          
But the authors conclude that treatment rates should improve in the interferon-free era, although the costs of DAA therapy could limit participation.
          
“The number of patients eligible for treatment will increase significantly as DAA therapies are recommended now in patients with decompensated cirrhosis,” Philip Vutien, MD, one of the study’s authors from Stanford University Medical Center, Palo Alto, California, said. “In addition, as DAA therapies are much better tolerated, we would expect patients and their providers to be much more willing to initiate treatment.”

No comments:

Post a Comment